NFE2L2 and diabetic kidney disease: As observed, there are completed and currently ongoing trials that investigate novel molecules and compounds, which exert antioxidant effects via regulation of the NRF2/KEAP1/ARE pathway and, hence, hold potential as new therapeutic targets in DKD management (Table 2).